KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) Equity Average (2016 - 2025)

Historic Equity Average for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $7.1 billion.

  • Bio-Rad Laboratories' Equity Average rose 94.76% to $7.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.1 billion, marking a year-over-year increase of 94.76%. This contributed to the annual value of $7.0 billion for FY2025, which is 840.99% down from last year.
  • Bio-Rad Laboratories' Equity Average amounted to $7.1 billion in Q4 2025, which was up 94.76% from $6.9 billion recorded in Q3 2025.
  • Bio-Rad Laboratories' Equity Average's 5-year high stood at $14.5 billion during Q4 2021, with a 5-year trough of $6.6 billion in Q1 2025.
  • For the 5-year period, Bio-Rad Laboratories' Equity Average averaged around $9.1 billion, with its median value being $8.8 billion (2022).
  • As far as peak fluctuations go, Bio-Rad Laboratories' Equity Average soared by 7014.04% in 2021, and later plummeted by 3764.94% in 2022.
  • Bio-Rad Laboratories' Equity Average (Quarter) stood at $14.5 billion in 2021, then tumbled by 37.65% to $9.0 billion in 2022, then decreased by 5.17% to $8.6 billion in 2023, then fell by 18.07% to $7.0 billion in 2024, then increased by 0.95% to $7.1 billion in 2025.
  • Its Equity Average was $7.1 billion in Q4 2025, compared to $6.9 billion in Q3 2025 and $6.9 billion in Q2 2025.